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PAGE EIGHT 
by Daniel Schnorbus 
The AIDS Project is happy to report the continuing 
progress of our "Immediate Seating" program. 
Through "Immediate Seating", clients of TAP can 
request free tickets to attend cultural events in the 
Portland area. These events include theater perfor-
mances and choral concerts, among other events. 
Various sponsors donate passes to a variety of 
cultural and entertainment events throughout the year. 
Among our sponsors are Maine Arts and the Maine 
Gay Men's Chorus. With such donations, "Immediate 
Seating" is kept vibrant. We thank our sponsors for 
their generosity in the past and look forward to working 
with them in the future. 
If you would like to participate in the "Immediate 
Seating" program, please call or visit me, Daniel 
Schnorbus, at The AIDS Project and fill out an "Imme-
diate Seating" Ticket Request Form. Please do so at 
least seven days prior to the event you wish to attend. 
Keep in mind that the sooner the request is made the 
better the chances are of securing tickets. You will be 
notified shortly after your request is made if TAP can 
get tickets for you. 
I look forward to hearing from you and hope to see 
you in the office soon. 
Client Services, Support Groups, and For Your To contact Daniel Schnorbus, TAP's Client 
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PageO~~ In The Affirmative © January 1999 from Bald Man Publishing for The AIDS Project, Portland, ME 
A man should stay alive if only out of curiosity. 
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As a person who has four cats, you might think 
that my favorite quote about curiosity would be 
"Curiosity killed the cat." No so. The Yiddish proverb 
above is more to my liking and has a more applicable 
reference to my own life. 
Almost thirteen years ago I suffered a very 
serious bout of depression and anxiety. It was easily the 
most awful time of my life. As bad as I felt, I had no 
serious thoughts of suicide. Curiosity kept me going. I 
just had a feeling that there was something or some 
things I was meant to be around for. Facetiously I would 
tell people that the thing I was meant to be around for 
was the revealing of the identification of "Deep Throat", 
the anonymous source for Woodward and Bernstein's 
Watergate stories. The truth was more intangible. 
Given that a third of my life has happened after 
that terrible depression, I am of the opinion that there 
have been many things I was meant to be here for, and 
that there are more still to come. Many of them are 
very personal and involve my family. Some are more 
general and involve the world around us all. One reason 
for my being here is all about being HIV-positive. 
Almost eleven years ago, I tested positive for 
HIV. In that time I have met an incredible number of very 
fine people. Some are HIV-positive, some are not. Some 
have AIDS, some have died of AIDS. I feel I was meant 
to meet them all. One group in particular that I feel I was 
meant to meet is a bunch of guys with HIV who banded 
together in a support group and in a social way, with 
dinners, cookouts, card playing, and friendship. Their 
strength and perseverance has been a real lesson in the 
meaning of being alive. 
On New Year's Eve, it is a tradition of some of the 
guys to get together and celebrate the fact that we're 
still here. We meet at one of the guys' house and play 
cards, eat ourselves silly, watch the ball drop in Time 
Square, and stay overnight to have the first breakfast of 
the new year together. We've been doing this for years. 
We've lost too many of the gang to AIDS. We are 
amazed and pleased to have survived. Four of us have 
been around the longest. We're certainly curious why 
this is so, but we don't know the answer. We would like 
to be around when the answer is found, when the cure 
for Al OS is found. 
Personally, I still feel like there are things I am 
meant to be here for. Doing this newsletter qualifies as 
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one of those things. With this issue, we begin our sixth 
year with the 39th edition and a collective 322 pages. 
That would make a good size novel. Our first edition 
came out in December 1993. We reported that Maine 
had a collective 443 cases of AIDS since reporting had 
begun. In this issue the number of cases is up to 832. By 
December of 1993, 228 deaths from AIDS had been 
reported in Maine. That figure is now 443. My curiosity 
is focused on how and when those figures will cease to 
become larger; how and when people will stop dying of 
this disease. 
If for no other reason, I might as well stay alive 
out of curiosity. And I hope along the way to do some 
good. My curiosity has led me into situations that have 
allowed me to do some good things since testing 
positive. I do a fair amount of volunteer work for The 
AIDS Project by serving on its Board of Directors. It has 
allowed me to have a small impact in a positive way, I 
hope, to improve the agency's services for clients. It 
has also given me the opportunity, as I said before, to 
meet some of the most interesting people, people who 
are infected and affected by HIV/AIDS. 
Curiosity has been a big factor in my life. I like to 
know things. I like to know how things work. I like to 
know how people behave. I like to know how people 
build their lives. My curiosity is like life itself -- always 
happening, always adapting, always striving to survive. 
As winter slows us down with its variety of 
snow, sleet, rain, and freezing cold, this is the time of 
year when I think about the future the most. I am very 
curious about my own personal future. What will 
happen to my family in the coming years? What about 
my friends? What about our state and nation? And 
irreverently, who is "Deep Throat"? (And even more 
irreverently, if the groundhog sees his shadow, will we 
have six more weeks of Clinton's Senate trial?) Who 
among our gang will survive to attend next year's New 
Year's Eve party? 
And given all this curiosity, perhaps I am meant 
to be right where I am. It's not a bad place to be, HIV 
aside. Of course, it's impossible to put aside the HIV for 
very long. It's always here. Still, with time has come the 
realization that living with HIV is better than not living at 
all. And it is better to live in spite of HIV. I guess I am just 
too damn curious about what is to come to let HIV stop 
me from living an interesting life. 
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Robert Moore is 
TAP's African-American Outreach Worker 
Hi Cumberland County, 
My name is Robert Moore and I am the African-American 
Outreach Worker of TAP's Prevention Education Department. If you 
need HIV literature, condoms, one-on-one conversation, public 
speakers for educational events, and/or referrals for counseling, call 
orwriteto me. 
Robert Moore 
The AIDS Project 
P.O. Box 5305 
Portland, ME 04101 
77 4-6877, ext. 12 
The AIDS Project 
615 Congress Street - 6th Floor 
(or 142 High Street) 
P.O. Box 5305 
Portland, Maine 04101 
Phone: 774-6877 Fax: 879-0761 
E-mail: tap@aidsproject.org 
Website: www.aidsproject.org 
AIDS Hotline: 775-1267 
or 1-800-851-2437 
Oxford/ Androscoggin Cty. Office 
One Auburn Center/Box 14L 
Auburn, ME 04210 
Phone: 783-4301 Fax: 795-4084 
York County Office 
Lafayette Center - 4th Floor 
Kennebunk, ME 04043 
Phone: 985-8199 
Fax: 985-8646 *51 
Staff: 
Doug Bailey, 
HAVEN I Housing Coordinator 
Declan Buckley, 
MSM Outreach Worker 
Diana Carrigan, 
Androscoggin and Oxford Counties 
Case Manager 
Janine Collins, 
Cumberland County Case Manager 
John Cronin, 
MSM Outreach Worker 
Caroline Curtis, 
Case Management Intern 
Sequoia Dance, 
Street Outreach Worker 
Douglas Eaton, 
Program Coord. of HIV Prevention 
Denise Ferrer, 
York County Case Mngmt. Intern 
Jill Frame, 
HAVEN Case Manager 
George W. Friou, 
Executive Director 
Demetra Giatas, 
Development Director 
John Green, 
HIV Case Manager 
John Holverson, 
Director of Policy & Program 
Gloria Leach, 
Community HIV Prev. Educator 
Annette Lemek, 
Case Management Intern 
Randy May, 
Director of Support Services 
Robert Moore, 
African-American Outreach Worker 
Rebecca Neel, 
Cumberland and York Counties 
Case Manager 
Susan Parr, 
Cumberland County Case Manager 
Getty Payson, 
York County Case Manager 
Steve Reevy, 
Manager I Finance & Administration 
Daniel Schnorbus, 
Client Services Coordinator 
Gerry Scoppettuolo, 
York County Field Outreach Worker 
David Aaron Swander, 
Education I Development Assistant 
Kerry S. Tardiff, 
Admin. I Case Mngmt. Assistant 
Art Waller, 
Accounting Assistant 
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Board of Directors: 
Joel C. Martin, Esq., President 
Michael Martin, Vice President 
Anne M. Romano, CPA, Treasurer 
JoAnne Peterson, Secretary 
Lawrence Bliss 
Michael Burnham 
Jerrold C. Edelberg, Ph.D. 
Dino Giamatti 
Judi Mansing 
Karla B. McGowan 
Frances W. Peabody 
John Wade 
Christopher Warner 
Verne Weisberg, M.D. 
Roberta M. Wright 
Advisory Board: 
Bettsanne Holmes, Chair 
Josiah K. Adams 
Peter C Barnard 
Joan B. Burns 
Peter L. Chandler, CPA 
Madeleine G. Corson 
Maria P. Damerel 
Josiah H. Drummond, Jr. 
Alice Gemmer 
Pamela W. Gleichman 
Sandra Goolden 
Celeste Gosselin 
Jonathan W. Karol, D.0. 
Leo J. LaPlante, CPA 
Pamela Knowles Lawrason, Esq. 
George M. Lord 
Mallory K. Marshall 
Mary Jean Mork 
Gwendolyn C. O'Guin, D.0. 
Patricia M. Pinto 
Lois Galgay Reckitt 
Victoria A. Rochefort 
Lynn E. Shaffer 
Elizabeth 0. Shorr 
John H. Siegle, M.D. 
Cynthia Sortwell, M.D. 
Seth Sprague 
James F. Tomney 
Virginia W. Truesdale 
Margaret Wiles 
Jean T. Wilkinson 
Margo Wintersteen 
Roger F. Woodman 
Frances R. Zilkha 
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Wellness & You Fitness Program 
for People vvith HIV/AIDS 
by Daniel Schnorbus 
Wellness & You is a nationally recognized stress 
reduction and physical activity program designed specif-
ically for people living with HIV and AIDS. In this pro-
gram individuals can participate in a variety of super-
vised physical activity, education, and specialized stress 
management segments. Weekly guest speakers address a 
variety of stress reduction methods, ranging from mas-
sage therapy to 1neditation. Moderate physical activity, 
including cardiovascular exercise and strength training, 
is aimed at improving the health and well being of people 
with HIV and AIDS. 
Those clients interested in participating in the 
Wellness & You Program will again have the opportunity 
to do so starting January 25, 1999. The sessions will last 
for twelve weeks and run through April 16, 1999. This 
group will meet Monday, Wednesday, and Friday morn-
ings at 10 a.m. at the Westbrook College campus of the 
University ofN ew England. 
Individuals interested in the Wellness & You Program 
can contact me, Daniel Schnorbus, at TAP at 774-6877, 
or Judy Vezina, the program's facilitator, at _797-7688, 
extension 4348. Please consider that there is an enroll-
ment process that includes a health screening and fitness 
assessment. Clients wishing to participate should contact 
one of us as soon as possible. 
Maine 
AIDS 
Maine Cases of AIDS - 832 
Maine Deaths from AIDS - 443 
U.S. Cases of AIDS -641,068 
U d 
U.S. Deaths from AIDS -390,692 
P ate " . . b Includes a11 cases smce reporting egan. 
Maine stats as of 9/98; U.S. stats as of 12/97. 
Maine AIDS Cases include only those who 
resided in Maine at the time of their diagnosis. 
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Do Drugs Cost Too Much? Consider Testosterone May Lessen Depression in Bring HIV Campaign Out of the Dark Alley 
the Alternatives AIDS Patients Wall Street Journal (12/15/98) 
Wall Street Journal (11/14/98) Infectious Disease News (11/98) 
Richard Jay Kogan, chairman and 
CEO of drug company Schering-Plough, 
asserts that the increasing profits by 
drug manufacturers are due to new drug 
candidates, better medications, novel 
delivery systems, and treatments for 
diseases that were previously untreat-
able. 
Commenting in the Wall Street 
Journal, Kogan notes that "the launch of 
new drugs shifts costs and benefits 
around in ways that confuse and 
infuriate many people." He adds that the 
costs are largely borne by health plans 
and health-care institutions. New drugs 
can reduce the incidence and severity of 
diseases on a large scale and can 
increase life span for infected individu-
als. 
The author cites the recent decline in 
the AIDS mortality associated with the 
benefits of new medication. One study 
found that combination therapy for HIV 
resulted in a 39 percent decrease in 
admissions, a 44 percent reduction in 
bed days, a 54 percent reduction in 
serious HIV-related illness, and a 40 
percent decline in the AIDS death rate. 
Additionally, progression to AIDS 
declined 42 percent. 
While the cost of the drugs is high, 
Kogan argues that they have reduced 
the total cost related to HIV. Attempts to 
decrease profits for drug companies, 
Kogan says, may result in a decline in 
pharmaceutical innovations. 
ABT-378 Shows Promise 
American Druggist (11/98) 
Preliminary data from a study of 35 
people receiving Abbott Laboratories' 
ABT-378, a 2nd-generation HIV protease 
inhibitor, indicate that the drug can be 
used to successfully lower viral loads. In 
the study, 16 of 17 treatment-naive 
people receiving the medication in 
conjunction with ritonavir had their viral 
loads fall to 400 copies per ml or lower 
over 20 weeks of therapy. Co-
Researchers from the New York State 
Psychiatric Institute found that biweekly 
injections of testosterone cypionate over 
three-months increased energy levels and 
feelings of well-being in a placebo-controlled 
study of 66 HIV-positive subjects. Dr. Glenn 
Wagner, a research scientist at the institute, 
said that fatigue is fairly common in HIV-
infected individuals, particularly those with 
late stage HIV. While there is no data indicating 
that anti-HIV medication decreases testoster-
one levels, other medications have been 
shown to decrease hormone levels. However, 
some researchers also differentiated between 
fatigue and clinical depression. 
Some researchers question whether the 
patient fatigue is caused by depression or by 
cytokine regulation. One six-month study of 80 
people with HIV showed that length of time on 
AIDS therapy was a good predictor of 
depression, as was older age, negative 
feelings about the future, and loss of motiva-
tion. 
lndinavir Stones Can Persist for Long 
Periods in HIV-Positive Patients 
Reuters (01/06/99) 
Researchers at Walter Reed Medical Center 
in Washington, D.C., report two cases of 
prolonged indinavir-associated kidney stones 
in HIV-positive patients who had interrupted 
indinavir treatment. In the December issue of 
Clinical Infectious Diseases, Ors. Mark E. 
Polhemus and Naomi E. Aronson reported that 
· two HIV-positive men who stopped indinavir 
treatment due to kidney stones still had the 
problem after six months without the 
medication. One patient had the kidney stones 
for 11 months after indinavir treatment was 
stopped. The researchers note that while 
indinavir cessation is the conservative 
treatment for HIV-infected patients with 
kidney stones, not all cases resolve with 
conservative treatment, and physicians 
should strongly consider withdrawing 
indinavir with any episode of indinavir-
associated kidney stones. 
In a letter to the editor of the Wall Street 
Journal, Daniel Zingale, the executive director 
of AIDS Action, applauded a recent editorial in 
the newspaper opposing public opinion 
campaigns that portray everyone as "at risk" 
for HIV. Zingale notes that homosexual men 
and injection drug users and their sex partners 
are at the highest risk in the United States. He 
asserts, though, that limiting a campaign 
solely to those two groups would result in a 
failure to reach other high risk groups, 
including young people and low-income 
minority women. 
Half of the 40,000 new HIV infections in the 
United States each year occur among young 
people. Zingale states that many younger 
people are still not completely educated about 
the disease, with some believing that new 
anti-HIV medications are capable of essen-
tially curing infection. He adds that the drugs 
are expensive and do not work for everyone. 
Hospitals Get $6 Million for HIV Brain Bank 
Boston Globe Online (12/15/98) 
The National Institutes of Health will give a 
$6 million grant to three New York City 
hospitals to study the neurological effects of 
HIV on the brain. Mount Sinai School of 
Medicine, Beth Israel Medical Center, and St. 
Luke's-Roosevelt Hospital Center will in turn 
create the Manhattan HIV Brain Bank, a 
collection of brains from people who died of 
AIDS. Researchers from around the country 
will be able to apply to the brain bank for tissue 
samples. 
Dr. Susan Morgello, the principle investiga-
tor of the project, explained that "this provides 
a really needed basic resource for research." 
The program will attempt to recruit about 90 
people a year for the brain donations, asking 
patients in the final stages of AIDS to undergo 
neurological and psychiatric evaluation and to 
donate their brains when they die. The 
researchers hope to identify whether HIV can 
latently infect the brain and nervous system, 
to determine the impact of brain infection with 
HIV, and to devise new drug therapies against 
HIV and HIV-associated disorders. 
administration with ritonavir increased "Hope sees the invisible, feels the intangible, 
the bioavailability of ABT-378. Kim and achieves the impossible." 
Madory, a spokesperson for Abbott, 
said that it could still be months before - Anonymous ;-'- .~. 
phase Ill trials begin. 
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HIV Type 1 in Semen of Men Receiving Challenging the 
Highly Active Antiretroviral Therapy Conventional Stance on Al DS 
New Eng. Jml. of Med. (12/17/98) New York Times (12/22/98) 
Researchers from Thomas Jefferson 
University in Philadelphia, Pa., detected 
proviral DNA from HIV in the seminal 
cells of HIV-1-infected men receiving 
highly active antiretroviral therapy who 
had no detectable levels of viral RNA in 
their plasma. The finding suggests that 
the virus can be sexually transmitted by 
infected men who appear to be in 
remission. 
The researchers, led by Dr. Hui Zhang, 
found proviral DNA in the seminal cells 
of four of seven men tested. Two men 
showed replication-competent viruses 
in their seminal cells. According to the 
researchers, Uthe viruses recovered 
from the seminal cells had no genotypic 
mutations suggestive of resistance to 
antiretroviral drugs and were 
macrophage-tropic, a feature that is 
characteristic of HIV-1 strains that are 
capable of being sexually transmitted." 
Glaxo Wins Approval for New AIDS 
Drug Despite Serious Risks 
Wall Street Journal (12/21/98) 
Glaxo Wellcome's newest AIDS drug, 
Ziagen, was approved for marketing by 
the Food and Drug Administration, even 
though clinical trials showed that about 
5 percent of patients experienced 
significant, and in some cases, fatal side 
effects, including fever, nausea, 
abdominal pain, low blood pressure, and 
an enlarged liver. 
Despite the potential drawbacks, the 
FDA approved Ziagen because it is used 
to treat a life-threatening disease and 
may allow some patients to discontinue 
the use of drug ucocktails" that are the 
standard in AIDS treatment today. 
While many patients currently take as 
many as 20 pills a day, patients who can 
tolerate Ziagen in combination with 
another AIDS drug, such as Glaxo's 
Combivir, would have to only take about 
four pills a day. Ziagen, a nucleoside 
analogue reverse transcriptase inhibitor, 
is the fourth AIDS drug Glaxo has 
developed. 
Conspiracy theories about HIV still abound 
despite a wealth of available scientific 
evidence. Recently, the Rev. Al Sharpton and 
his National Action Network sponsored the 
Harlem AIDS Forum, which featured many 
outspoken opponents to traditional views on 
HIV and AIDS. Of approximately 12 speakers, 
only one believed that HIV is the cause of 
AIDS, but he also argued that the virus was 
being spread to people of color throughout the 
world through the World Health Organization 
via its vaccine programs. Event organizer 
Curtis Cost explained that the objective of the 
meeting uwas to allow people to hear 
disparate perspectives, and to do their own 
research." 
According to a survey conducted by the 
Institute of Minority Health Research at Emory 
University's Rollins School of Health, 74 
percent of African-Americans questioned 
believed they were very likely or somewhat 
likely to be used as test subjects for studies 
without their consent. Eighteen percent 
reported that they believe that HIV was an 
engineered virus and almost 10 percent said 
that AIDS is part of a genocidal plot to kill black 
people. 
The AIDS epidemic has been particularly 
prevalent in the African-American community; 
although African-Americans comprise only 13 
percent of the United State's total population, 
they accounted for 57 percent of new 
infections last year, according to the Centers 
for Disease Control and Prevention. Some 
AIDS activists among the community 
disapprove of the conspiracy theories, 
asserting that they serve to subvert prevention 
efforts such as testing and safe sex. 
"While there is a chance of 
the world getting through its 
troubles, I hold that a reason-
able man has to behave as 
though he were sure ofit. If at 
the end your cheerfulness is 
not justified, at any rate you 
will have been cheerful." 
-H. G. Wells 
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Controversy Rages Over Reporting Naming 
Names of HIV-positives 
Seattle Times Online (12/28/98) 
Across the nation, debate is raging over the 
use of name reporting for HIV-infected people. 
Texas has decided to abandon the use of 
unique identifier codes that allow for anony-
mous HIV surveillance, instead opting to 
report cases by name. Texas tried the non-
name based reporting system for four years. 
Many AIDS activists are in favor of the 
unique identifier system for the sake of patient 
confidentiality. Maryland has used the system 
as long as Texas, reporting no problems with 
its surveillance ability. Thirty-two states thus 
far have adopted some form of HIV reporting, 
but Texas and Maryland are the only two that 
used unique identifiers. 
Proponents of non-name based testing 
assert that the reporting of names will result in 
a decrease in the number of people willing to 
gettested for HIV. 
However, Surgeon General David Satcher 
notes, "Using names discourages testing only 
for those who don't understand the system. 
What they see as a risk is greatly exagger-
ated." 
The Centers for Disease Control and 
Prevention recently recommended the use of 
name-based reporting, but leaves the decision 
up to individual states. 
Role of HHV-8 in HIV-Related Kaposi's 
Sarcoma Confirmed 
Reuters (12/29/98) 
Researchers from the Amsterdam Cohort 
Studies on HIV Infection and AIDS report data 
that "strongly confirm" the causal role of 
human herpesvirus-8 (HHV-8) in Kaposi's 
sarcoma (KS). The authors studied over 1.400 
homosexual men and more than 1, 100 drug 
addicts to determine the presence of 
antibodies to HHV-8 antigens. 
According to the findings, there was a low 
prevalence of HHV-8 seropositivity among 
drug users with a low incidence of KS, while 
the high prevalence of HHV-8 seropositivity 
among the homosexual men paralleled a high 
incidence of KS in that cohort. The study was 
reported in the Dec. 24 issue of AIDS. 
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A U.S. Appeals Court ruled that Maine 
dentist Randon Bragdon violated the 
1990 American with Disabilities Act by 
refusing to treat an HIV-infected woman 
in his office for fear of contracting the 
disease. Bragdon had suggested filling 
the woman's cavity in a hospital instead, 
which he said would offer greater 
precautions against HIV infection; 
however, Sidney Abbott refused 
because the in-hospital procedure 
would have cost her $185, while the 
office procedure would have been just 
$35. 
The case reached the appeals court 
after the Supreme Court sent it back for 
reconsideration. The dentist's attorney 
noted that the Supreme Court, which 
ruled in June that HIV-infected individu-
als are protected by the ADA, unless 
they pose "a direct threat to the health 
and safety of others," may be asked to 
reconsider his client's case. Under 
federal law, Bragdon may be held liable 
for Abbott's legal expenses. 
Peripheral Neuropathy/Myopathy 
Common Side Effects of HIV 
Antiretrovirals 
Reuters (12/30/98) 
New York Times (01/05/99) 
Clinical trials sometimes entail ethical 
dilemmas because the purpose of many 
studies is not to help treat patients but to 
gather information that could eventually help 
others. However, many people who sign up for 
trials view the experimental drugs as 
beneficial treatments, despite the fact that the 
drugs may not help the subject. 
George Annas, chairman of the health law 
department at Boston University School of 
Public Health, explains that "sick people can't 
think of themselves as research subjects. 
They don't want to feel like they're being used 
as guinea pigs." Some patients become 
involved in the trials because they cannot 
afford other treatment. In addition, some AIDS 
and hepatitis C advocacy groups have taken 
up treatment issues, supporting the rights of 
subjects involved in clinical trials. 
In one study of a hepatitis C treatment, viral 
load results were withheld until the trial 's end 
in order to retain as many subjects as possible. 
Advocates believe that the practice is 
unethical because it limits treatment options 
and does not allow patients to assess their 
progress. The practice is not found in HIV 
clinical trials due to the strong advocacy 
groups and community advisory groups 
available to HIV-infected individuals. 
Members of an AIDS Clinical Trials Increase in Heterosexually Acquired HIV 
Group report that therapy with currently Infection Validated 
recommended antiretroviral drugs for 
HIV infection could produce symmetri-
cal neuropathy (nerve disease) and 
myopathy (skeletal muscle disease). Of 
nearly 2,500 patients studied, 222 site 
diagnoses of neuropathy were made, 
about half of which were cases of distal 
symmetrical neuropathy. Patients 
receiving zidovudine and zalcitabine had 
the highest rates of distal symmetrical 
neuropathy. 
The researchers, who reported their 
findings in the Dec. 24 issue of AIDS, 
said that because neuromuscular 
complications are common 
antiretroviral therapy-related effects, 
dose modifications may be required. 
A Correction 
In last month's newsletter, I spelled Kerry 
Tardiff's name incorrectly-- twice and in different 
ways both times. My apology to Kerry and my 
thanks for her fine work on getting this newsletter 
distributed to all our readers. 
Reuters (01/05/99) 
Researchers from the CDC report in the 
January issue of the American Journal of 
Epidemiology that most patients with 
heterosexually acquired AIDS have a valid 
heterosexual risk of exposure to HIV, support-
ing reports of an emerging heterosexual AIDS 
epidemic in the United States. Researchers at 
the CDC investigated heterosexual risk among 
almost 2,000 patients (aged 13 years or older) 
who reported heterosexual risk or no risk for 
HIV infection; heterosexual risk was validated 
in 82 percent of the subjects. 
About one-fifth of the men and over half of 
the women who initially reported no risk 
factors for the virus were determined to have 
most likely contracted HIV heterosexually. The 
CDC suggests that heath care workers make 
determined efforts to identify and record 
accurate information for people infected with 
HIV and that there be periodic re-examination 
of patient risk factors to ensure data accuracy. 
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Dual HIV Infection Cases Not So Rare 
AIDS Alert (12/98) 
Scientists previously believed that dual 
infection with multiple strains of HIV occurred 
only in rare cases, but new data show that 
dual-infection cases may be more common 
than formerly thought. Researchers in 
Alabama investigated HIV-infected chimpan-
zees that were exposed to an unrelated HIV-1 
strain. Using PCR tests of cellular DNA from 
blood and lymph nodes, the researchers found 
that they could identify the second strain, but 
only within the first six weeks of exposure to 
the second HIV strain. 
According to Dr. Fultz, one of the research-
ers, the finding "indicated that the prior 
infection was down-regulating and bringing 
under control the second strain that the animal 
was exposed to, which is what you would like 
in a vaccine." Even universal primers did not 
pick up the second strain in some animals. 
Using PCR primers to the strains that had 
infected the animals, the scientists found that 
almost every animal was, in fact, infected with 
a second strain, indicating that primers 
preferentially pick up one strain. Fultz said she 
is not optimistic about the ability of existing 
methods to detect secondary strains. 
AIDS Vaccines Look Good in Tests 
San Francisco Examiner Online {12/27/98) 
Even though several AIDS experts are 
confident that developing a vaccine against 
AIDS by President Clinton's goal of 2007 is an 
attainable objective, a NIH report that said that 
creating an effective vaccine will require a 
tremendous undertaking has received the 
support of researchers such as R. Scott Hitt, 
chairman of Clinton's advisory council on 
HIV/AIDS, who believes that developing a 
vaccine within 10 years will take more effort or 
good luck. Anthony Fauci, director of the 
NIAID, and an advocate of Clinton's goal, has 
pointed out that one of three vaccines in late-
stage development could be the first to make a 
breakthrough, including VaxGen's AIDSVax, 
which is in Phase Ill trials to determine 
whether the antibodies stimulated by the 
genetically engineered vaccine attack HIV. 
Using a different approach, Wyeth-Lederle 
Vaccines is developing a vaccine that involves 
injecting a small amount of HIV DNA into a 
person's muscle to stimulate the production of 
antibodies against the virus. Pasteur-Merieux 
Connaught is working on a so-called vectored 
vaccine, currently in Phase II trials. '"A~ 
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W MEDICAL ASSISTANT FUNDS CJ An important reminder to clients: 
- There are funds available to TAP clients with financial need for >a: the following items: Routine Dental Care, Routine Eye Care and 
Eyeglasses, Vitamin Supplements, Non-Prescription Skin Care 
W Products, and Non-Medicaid Medication Co-pays. en There is a dollar limit to how much a client can receive in any 
fiscal year. Contact your case manager for assistance. 
!z FREE LUNCH 
UJ 
.....J 
u 
Enjoy a free lunch at The AIDS Project every Thursday at noon. 
Join other clients and TAP staff for a great meal, good conversa-
tion, and very good company. Drop on by Thursdays at noon! 
IMMEDIATE SEATING 
For free tickets to area events as they become available, sign up 
for "Immediate Seating." Call TAP at 774-6877 for more 
information. 
I.V LEAGUE 
Meetings of the I.V. League support group are held on 
Wednesdays at 11 :00 a.m. at the Parkside Community Center, 
94 Mellen Street, in Portland. 
For more information, call 874-8775. 
THE MEETING PLACE 
This room is used by TAP in Portland for support groups, 
counseling and testing, and some client/case manager 
meetings. Located in Suite 632, it provides more privacy for 
people served by TAP. 
Enter from the High Street side of the building. 
2 TAP ON-LINE Q Visit our new website at "www.aidsproject.org" 
_ To e-mail The AIDS Project, 
L- send your message along to ''tap@aidsproject.org" j ~:~k~~!~~!i~~ 
a: 
0 
www.hivpositive.com 
www.thebody.com 
www.projinf.org 
U. for info on HIV and AIDS. 
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a. PROJEtT 
::::) FOR PEOPLE INFECTED Q AND AFFECTED BY HIV/AIDS 
a: TUESDAYS 
CJ Time: 10:30 a.m. to noon 
J- Group: HIV Infected/Affected Drop-In Support Group ~ A meeting for people living with and affected by the virus. 
CL Location: Portland, TAP, The Meeting Place, Suite 632. 
CL Contact Randy May at TAP at 77 4-6877 for more info. 
:::) 
(/) Time: 1 :30 p.m. to 3:00 p.m. 
Group: People Living with HIV 
A drop-in support group for people living with HIV. 
Location: Auburn, TAP, One Auburn Center. 
Contact Diana Carrigan at TAP at 783-4301 for more info. 
THURSDAYS 
Time: 10:00 a.m. to 11 :30 a.m. 
Group: HIV Infected/Affected Drop-in Group 
A TAP-sponsored meeting for people 
living with and affected by HIV/ AIDS in southern Maine. 
Location: Sanford, Unitarian Church, located at the corner 
of Main St. (Rte. 109) and Lebanon St. (Rte. 202). 
Contact Getty Payson at TAP at 985-8199 for more info. 
Time: 12 noon 
Group: Open Lunch for TAP Clients/Staff 
An informal luncheon gathering ofTAP staff and clients. 
Location: Portland, TAP, Conference Room. 
Contact Randy May at TAP at 77 4-6877 for more info. 
Time: 5:30 p.m. to 7:00 p.m. 
Group: People Living with HIV/AIDS 
A drop-in support group for anyone with HIV/ AIDS. 
Location: Portland, TAP, The Meeting Place, Suite 632. 
Contact Randy May at TAP at 77 4-6877 for more info. 
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Sources for some of the information in this 
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Questions about HIV/AIDS? 
Call toll-free 
National AIDS Hotline: 
1-800-342-2437 
Maine AIDSline: 
1-800-851-2437 
Maine Teen Hotline: 
1-800-851-2437 
In The Affirmative is a monthly newsletter published 
by The AIDS Project for people living with and affected 
by HIV/ AIDS. Letters, articles, or other submissions 
should be sent to: In The Affirmative, c/o The AIDS 
Project, P.O. Box 5305, Portland, ME 04101, or call 
(207) 774-6877. Submissions can be printed 
anonymously as long as the person submitting the 
material includes his or her name and phone number for 
verification. 
newsletter include: 
CDC HIV/STD/TB Prevention News Update 
Contributors include: 
Janine Collins 
Robert Moore 
LL 
(on Wednesdays from 6-9pm) 
News, information, and features are as up-to-date 
as possible prior to publication. Any medical 
information included in this newsletter is submitted for 
the reader's information only, to be used as the reader 
so chooses. 
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